Epirubicin in Metastatic Breast Cancer Treatment
Author Information
Author(s): Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A
Primary Institution: National Cancer Institute, Naples, Italy
Hypothesis
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer after an epirubicin-containing adjuvant treatment?
Conclusion
Epirubicin should not be administered in combination with taxanes for metastatic breast cancer patients who have relapsed after anthracycline-based therapy.
Supporting Evidence
- Both treatment regimens showed similar antitumor activity.
- The median overall survival was 18 months for the combination and 21 months for docetaxel alone.
- Leucopenia, nausea, and stomatitis were significantly worse with the combination treatment.
Takeaway
The study found that adding epirubicin to docetaxel didn't help patients with metastatic breast cancer who had already received epirubicin before.
Methodology
Patients were randomly assigned to receive either docetaxel alone or a combination of docetaxel and epirubicin, with various evaluations and toxicity assessments conducted throughout the treatment.
Limitations
The study was stopped early due to slow recruitment and had a small sample size.
Participant Demographics
Women with metastatic breast cancer, median age 51, with a mix of premenopausal and postmenopausal statuses.
Statistical Information
P-Value
p=0.8196
Confidence Interval
95% exact CI: 51–88 for ED arm and 95% exact CI: 58–93 for D arm
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website